Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-3310-01 Phase I Study in Healthy Japanese Adult Males and CKD Patients with Type 2 Diabetes Mellitus
jRCT2071260026Phase 1Recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of ONO-3310 in chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM) (5 arms), sponsored by Ono Pharmaceutical. Primary endpoints: Safety and Tolerability and Pharmacokinetics. Started Jun 2026; status: recruiting.
02
Drugs
ONO-3310
03
Conditions
chronic kidney disease (CKD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2071260026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071260026.